New KRAS-Targeted Therapy Daraxonrasib Shows Promise for Pancreatic Cancer Treatment
- Daraxonrasib has secured breakthrough designation from the U.S.
- Pancreatic cancer ranks as one of the most aggressive malignancies.
- The disease is largely fueled by mutations in the KRAS oncogene.
Daraxonrasib has secured breakthrough designation from the U.S. Food and Drug Administration. The oral targeted therapy takes direct aim at mutations in the RAS gene family, which drive over 90% of pancreatic cancer cases.
The History of the ‘Undruggable’ KRAS Oncogene
Pancreatic cancer ranks as one of the most aggressive malignancies. Researchers at Memorial Sloan Kettering Cancer Center project it will become the second most deadly cancer in the United States by 2030.
The disease is largely fueled by mutations in the KRAS oncogene. This gene normally helps control normal cell growth.
When mutated, however, KRAS sends continuous signals that drive cancer cell proliferation. Historically, researchers considered KRAS “undruggable.”
That barrier began to shift with the discovery of targeted inhibitors addressing specific subtypes, such as G12C and G12D mutations. Sajid Khan, Vivekananda Budamagunta, and Daohong Zhou detailed this shift in an overview of therapeutic strategies published in Advances in Cancer Research.
Early-Phase Trial Results Show Promising Tumor Shrinkage
Gastrointestinal medical oncologist Eileen O’Reilly, MD, of Memorial Sloan Kettering Cancer Center presented early-phase clinical trial results at the Annual Meeting of the American Association of Cancer Research in April 2026. She noted that the treatment offers a potential alternative to standard chemotherapy for patients with metastatic disease.
Daraxonrasib demonstrated significant clinical activity.
According to Memorial Sloan Kettering data, the overall response rate reached 47%. This means tumors showed positive shrinkage or activity.
Progression-free survival at six months stood at 71%. Meanwhile, overall survival at six months reached 83%.
Overcoming Resistance Through Combination Strategies
Targeted therapies provide fresh avenues for intervention. Yet, drug resistance remains a major hurdle in pancreatic cancer treatment.
This challenge has prompted researchers to investigate various combination strategies. These approaches involve receptor tyrosine kinase, SHP2, and SOS1 inhibitors, alongside BCL-XL-selective degraders like DT2216.
Oral Administration Offers Practical Patient Benefits
Beyond raw survival data, daraxonrasib offers practical advantages for vulnerable patient populations.
Because the therapy is administered orally once a day, it may benefit older patients or individuals with other medical issues.
Memorial Sloan Kettering gastrointestinal medical oncologist Wungki Park, MD, led a separate trial for patients whose disease stopped responding to chemotherapy. He stated that the approach could represent a paradigm shift after more than three decades of reliance on chemotherapy.
Larger phase 3 trials comparing daraxonrasib directly to standard chemotherapy are currently underway.